GCP
OCUL icon

GSA Capital Partners’s Ocular Therapeutix OCUL Stock Holding History

GSA Capital Partners’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-35,098
Closed -$426K – 2041
2025
Q4 		$426K Sell
35,098
-80,455
-70% -$977K 0.04% 927
2025
Q3 		$1.35M Buy
+115,553
New +$1.38M 0.11% 228
2025
Q2 		– Sell
-15,306
Closed -$112K – 2031
2025
Q1 		$112K Buy
+15,306
New +$118K 0.01% 1485
2024
Q4 		– Sell
-126,681
Closed -$1.1M – 1903
2024
Q3 		$1.1M Buy
+126,681
New +$1.04M 0.08% 417
2024
Q2 		– Sell
-28,741
Closed -$262K – 1921
2024
Q1 		$262K Sell
28,741
-218,162
-88% -$1.55M 0.02% 1291
2023
Q4 		$1.1M Buy
246,903
+13,321
+6% +$39.4K 0.09% 343
2023
Q3 		$733K Buy
233,582
+114,629
+96% +$469K 0.06% 567
2023
Q2 		$614K Buy
+118,953
New +$707K 0.06% 616
2022
Q3 		– Sell
-127,978
Closed -$514K – 1774
2022
Q2 		$514K Buy
127,978
+70,358
+122% +$266K 0.08% 485
2022
Q1 		$285K Buy
+57,620
New +$319K 0.04% 928
2019
Q4 		– Sell
-11,222
Closed -$34K – 1639
2019
Q3 		$34K Buy
+11,222
New +$50.2K ﹤0.01% 1335
2018
Q2 		– Sell
-15,600
Closed -$102K – 1858
2018
Q1 		$102K Buy
+15,600
New +$87.8K 0.01% 1528
2015
Q3 		– Sell
-12,412
Closed -$261K – 1946
2015
Q2 		$261K Buy
+12,412
New +$308K 0.01% 1682

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GSA Capital Partners's OCUL Position: Q1 2026 in Review

GSA Capital Partners sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 35,098 shares — an estimated $426K sold.

GSA Capital Partners first reported a position in OCUL in Q2 2015 and held it in 13 quarters. The position peaked at $1.35M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • GSA Capital Partners reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 35,098 Ocular Therapeutix shares in Q1 2026, an estimated $426K.
  • GSA Capital Partners first reported a position in Ocular Therapeutix in Q2 2015 and held it in 13 quarters.
  • GSA Capital Partners's Ocular Therapeutix position peaked at $1.35M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.